Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2086766 | 0.79 | PARP1 (0.65) | PARP1 | |
| SCHEMBL15968615 | 0.69 | PARP1 (0.57) | PARP1 | |
| SCHEMBL14980870 | 0.68 | PARP1 (1.00) | PARP1 | |
| SCHEMBL2087627 | 0.68 | PARP1 (0.51) | PARP1 | |
| SCHEMBL2087564 | 0.67 | PARP1 (0.50) | PARP1 | |
| SCHEMBL2086911 | 0.66 | PARP1 (0.49) | PARP1 | |
| SCHEMBL14346099 | 0.65 | PARP1 (0.66) | PARP1 | |
| SCHEMBL12846279 | 0.64 | PARP1 (0.57) | PARP1 | |
| SCHEMBL12786036 | 0.64 | PARP1 (0.57) | PARP1 | |
| SCHEMBL12846124 | 0.64 | PARP1 (0.47) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771325-B2 | Tricyclic compounds and preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-09-26 | — | — | US | disclosed |
| US-9771325-B2 | Tricyclic compounds and preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-09-26 | — | — | US | disclosed |
| US-20160362371-A1 | NOVEL TRICYCLIC COMPOUNDS AND PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-12-15 | — | — | US | disclosed |
| US-20160362371-A1 | NOVEL TRICYCLIC COMPOUNDS AND PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-12-15 | — | — | US | disclosed |
| WO-2015121876-A1 | NOVEL TRICYCLIC COMPOUNDS AND PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-08-20 | — | — | WO | disclosed |
| US-8716493-B2 | Multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2066324-B1 | CYCLOALKANOPYROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS | CEPHALON INC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20110059959-A1 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF | CEPHALON, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2050750-B1 | Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | CEPHALON INC (US) | 2010-09-22 | — | — | EP | disclosed |
| EP-2050750-A2 | Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | CEPHALON, INC. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1754707-A2 | Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | CEPHALON, INC. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060276497-A1 | Novel multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| US-7122679-B2 | Multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1294725-B1 | MULTICYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PARP, VEGFR2 AND MLK3 ENZYMES | CEPHALON INC (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1294725-A2 | MULTICYCLIC COMPOUNDS AND THE USE THEREOF AS INHIBITORS OF PARP, VEGFR2 AND MLK3 ENZYMES | CEPHALON, INC. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020028815-A1 | Novel multicyclic compounds and the use thereof | CEPHALON, INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001085686-A2 | MULTICYCLIC COMPOUNDS AND THE USE AS INHIBITORS OF PARP, VEGFR2 AND MLK3 ENZYMES | CEPHALON, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276497-A1 | Novel multicyclic compounds and the use thereof | MLKL, PARP3, PARP1 | PARP1 3/4885 |
| US-20160362371-A1 | NOVEL TRICYCLIC COMPOUNDS AND PREPARATION THEREOF | CYP11B1, CYP11B2, CYP51A1 | PARP1 154/4885 |
| US-20020028815-A1 | Novel multicyclic compounds and the use thereof | MLKL, PARP3, PARP1 | PARP1 3/4885 |
| US-20110059959-A1 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF | MLKL, PARP3, PARP1 | PARP1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.